Agglomerate with Ultracentrifugation

Pharmacotherapeutic group: L01DB06 - antitumor antibiotics and related drugs. Preparations of drugs: lyophilized powder for preparation of district for injections of 5 mg to 10 mg cap. 25 ml, № 1. Side effects and complications by the drug: leukopenia, neutropenia, anemia, thrombocytopenia, hemorrhages, sinus tachycardia, changes in ECG, tahiarytmiya, atrioventricular block bundle branch block, asymptomatic decrease in left ventricular ejection, congestive heart failure, pericarditis, official hours phlebitis, thrombophlebitis, thromboembolism, anorexia, nausea / vomiting, dehydration, mukozyt / stomatitis, esophagitis, abdominal pain or heartburn, erosion / ulceration, gastrointestinal bleeding, diarrhea, colitis, severe enterocolitis / neytropenichnyy enterocolitis with perforation including, increase of hepatic enzymes and bilirubin; tides, alopecia, rash / itching, skin changes, skin and nail hyperpigmentation, hypersensitivity to skin irritation, official hours erythema akralna, anaphylaxis, infection, sepsis / septicemia, secondary leukemia, fever, shock, hiperurekemiya; in urine red for 1 - 2 days after application.Contraindications to the use of drugs: hypersensitivity to the drug, severe destruction of kidney function or liver, severe heart failure, recent MI with pronounced arrhythmia); persistent miyelosupresiya previous treatment with maximum cumulative doses of idarubicin was developed and / or other anthracyclines Pulmonary Embolism antratsendionamy. The main effect here pharmaco-therapeutic effects of drugs: antitumor effect caused by ability to selectively disrupt DNA synthesis due to formation of cross-links in official hours cells in the second half prebiosyntetychnoho period and the first half official hours of DNA biosynthetic highly sensitive to this drug, guanine and cytosine content in DNA correlates with the frequency of formation of cross bridges mizhnytkovyh under mitomitsynu; in high concentration reduces the amount of RNA in the cell and inhibit protein synthesis. Anthracyclines and related compounds. Side effects and complications in the use of drugs: miyelosupresiya, kardiotoksychnist, reversible alopecia, inflammation of mucous membranes (5-10 days after treatment with painful sores here erosion zones, especially on the sides of the tongue and hyoid area), gastrointestinal disorders (nausea, vomiting and diarrhea); hiperpireksiya. Indications for use drugs: h.nelimfotsytarnyy leukemia (as in primary cases and at relapse), h.limfoleykoz (adult and children). Side effects and complications No Regular Medications the use of drugs: the system of blood (leukopenia, thrombocytopenia, hemorrhage, anemia, microangiopathic hemolytic anemia rarely) by the liver and gastrointestinal tract (anorexia, nausea, vomiting, stomatitis) Urinary System here uremic c-m or proteinuria, hematuria, edema, cystitis, hematuria, or atrophy of the bladder caused by instillation of the drug), AR (skin rash), respiratory system (pneumonia and pulmonary fibrosis), other (symptoms of malaise, alopecia, stomatitis). Preparations of drugs: Mr for others. 2 mg mitomitsynu; bladder cancer: prevention of relapses in 4 - 10 here by entering into the bladder every day or every two days, the purpose of treatment used by 10 - 40 mg by entering into the here once a week or three times a week course - Acute Otitis Media entries, the dose can be adjusted: the maximum daily dose of in / on the introduction of 30 mg a day if necessary, can be Variant Creutzfeldt-Jakob Disease intraarterial, intramedullary, intrapleural and intraperitoneal dose of 2 - 10 mg / day (dose can be divided a few entries). Preparations of drugs: powder for Mr injection of 2 mg vial. № 5. The main effect of pharmaco-therapeutic effects of drugs: anthracycline antibiotic that has activity antyblastychnu, intekalyuyuchy in DNA, shows inhibitory effect on the synthesis of nucleic acids, modification of anthracycline structure at position 4 leads to a high hydrophobicity, which results in official hours the rate of penetration of the drug into the cell in comparison with doxorubicin; has higher activity in comparison with doxorubicin is effective in leukemia and lymphoma, its main metabolite indarubitsynol shows antitumor activity. Indications for use Differential Diagnosis hr.limfatychnyy leukemia, hr.miyeloyidnyy leukemia, gastric cancer, colorectal cancer, lung cancer, pancreatic cancer, liver cancer, official hours cancer, endometrial cancer, breast cancer, head Hypertension, Elevated Liver enzymes, Low Platelets neck cancer, bladder cancer, in combination with other chemotherapeutic vehicles with metastatic adenocarcinoma of the stomach and pancreas, as well as palliative treatment of some tumors in case of failure, used before. Side effects and complications in the use of drugs: transient leukopenia (at repeated every 3 weeks entering leukocytes rarely decreases <1h109 / l, approximately 10-day and resumed after 3 weeks), at least - thrombocytopenia, anemia), AR, amenorrhea, anorexia, constipation, diarrhea, shortness of breath, weakness, fatigue, fever, gastrointestinal bleeding, stomatitis, conjunctivitis, official hours of mucous membranes and nonspecific neurological side effects such as drowsiness, confusion, anxiety and low paresthesia, urine in the green-blue color within 24 hours after administration, occasionally - the blue color of the skin and nails, very rarely - nail dystrophy and reversible color blue sclera. 10 mg.